CA2686959C - Methods for detecting cardiac damage - Google Patents

Methods for detecting cardiac damage Download PDF

Info

Publication number
CA2686959C
CA2686959C CA2686959A CA2686959A CA2686959C CA 2686959 C CA2686959 C CA 2686959C CA 2686959 A CA2686959 A CA 2686959A CA 2686959 A CA2686959 A CA 2686959A CA 2686959 C CA2686959 C CA 2686959C
Authority
CA
Canada
Prior art keywords
ctni
ctnt
cardiac
heart
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2686959A
Other languages
English (en)
French (fr)
Other versions
CA2686959A1 (en
Inventor
Xinhua Yan
Anthony O. Caggiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Priority to CA2965208A priority Critical patent/CA2965208C/en
Publication of CA2686959A1 publication Critical patent/CA2686959A1/en
Application granted granted Critical
Publication of CA2686959C publication Critical patent/CA2686959C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
CA2686959A 2007-05-10 2008-05-12 Methods for detecting cardiac damage Active CA2686959C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2965208A CA2965208C (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92854107P 2007-05-10 2007-05-10
US60/928,541 2007-05-10
PCT/US2008/006060 WO2008140814A1 (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2965208A Division CA2965208C (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Publications (2)

Publication Number Publication Date
CA2686959A1 CA2686959A1 (en) 2008-11-20
CA2686959C true CA2686959C (en) 2017-06-13

Family

ID=40002559

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2686959A Active CA2686959C (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage
CA2965208A Active CA2965208C (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2965208A Active CA2965208C (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Country Status (11)

Country Link
US (5) US8628929B2 (enExample)
EP (1) EP2153228A4 (enExample)
JP (5) JP5749490B2 (enExample)
CN (2) CN101743474B (enExample)
AU (1) AU2008251822B2 (enExample)
BR (1) BRPI0810631A2 (enExample)
CA (2) CA2686959C (enExample)
IN (1) IN2014MN01227A (enExample)
MX (2) MX348082B (enExample)
RU (1) RU2498309C2 (enExample)
WO (1) WO2008140814A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348082B (es) * 2007-05-10 2017-05-25 Acorda Therapeutics Inc Metodos para detectar daño cardiaco.
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
US8835120B2 (en) * 2009-12-02 2014-09-16 Abbott Laboratories Assay for cardiac troponin-T (cTnT)
US8652788B2 (en) * 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
ES2627337T3 (es) * 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
RU2585391C1 (ru) * 2014-12-19 2016-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Чеченский государственный университет Способ иммунологического прогнозирования малых повреждений миокарда
EP3353546A1 (en) * 2015-09-25 2018-08-01 Douglas B. Sawyer Methods for treating cardiac injury
RU2648529C1 (ru) * 2016-12-27 2018-03-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ оценки эффективности лекарственной терапии у взрослых пациентов с острой сердечной недостаточностью после операций на открытом сердце, получающих лечение методом экстракорпоральной мембранной оксигенации
RU2709458C2 (ru) * 2017-12-22 2019-12-18 Марина Александровна Чичкова Способ оптимизации ранней иммунологической диагностики осложнений чрескожного коронарного вмешательства у пациентов с ИБС
RU2722111C1 (ru) * 2019-12-30 2020-05-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ ведения пациентов с хроническим лимфолейкозом в процессе полихимиотерапии по схеме fcr, направленный на предотвращение кардиотоксичности
RU2749552C1 (ru) * 2020-08-03 2021-06-15 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ отбора пациентов с длительно персистирующей формой фибрилляции предсердий на проведение эффективного катетерного лечения
RU2760242C1 (ru) * 2021-03-01 2021-11-23 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Способ оценки повреждения миокарда и риска развития осложнений после операций на сердце в условиях искусственного кровообращения
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5324502A (en) 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
US6092695A (en) 1992-05-11 2000-07-25 Cytologix Corporation Interchangeable liquid dispensing cartridge pump
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6653249B1 (en) * 2000-05-25 2003-11-25 Penn Emblem Corporation Emblem having calendered fabric layer
GB0029154D0 (en) * 2000-11-30 2001-01-17 Lee Helen Signal enhancement with multiple labelled-antibodies
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1267590C (zh) * 2004-06-11 2006-08-02 清华大学 一种用于组织修复的生长因子缓释体系的制备方法
CN1715926B (zh) * 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
US20070015777A1 (en) 2005-07-14 2007-01-18 Myogen, Inc. Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
MX348082B (es) 2007-05-10 2017-05-25 Acorda Therapeutics Inc Metodos para detectar daño cardiaco.
DE102007061117A1 (de) 2007-12-19 2009-06-25 Robert Bosch Gmbh Elektrische Kontaktierung
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
US9329171B2 (en) 2016-05-03
US20140378377A1 (en) 2014-12-25
AU2008251822B2 (en) 2014-02-06
CN104614510B (zh) 2017-07-04
JP5998171B2 (ja) 2016-09-28
IN2014MN01227A (enExample) 2015-07-03
BRPI0810631A2 (pt) 2017-05-09
JP6978553B2 (ja) 2021-12-08
JP6636402B2 (ja) 2020-01-29
US20180028610A1 (en) 2018-02-01
US20160263192A1 (en) 2016-09-15
CA2965208A1 (en) 2008-11-20
RU2498309C2 (ru) 2013-11-10
AU2008251822A1 (en) 2008-11-20
JP2020176138A (ja) 2020-10-29
US20110085976A1 (en) 2011-04-14
US9757429B2 (en) 2017-09-12
CA2686959A1 (en) 2008-11-20
EP2153228A1 (en) 2010-02-17
MX348082B (es) 2017-05-25
JP2014122923A (ja) 2014-07-03
CN101743474A (zh) 2010-06-16
JP2019010123A (ja) 2019-01-24
US20190269759A1 (en) 2019-09-05
RU2009145695A (ru) 2011-06-20
CN101743474B (zh) 2015-06-03
CN104614510A (zh) 2015-05-13
US10258667B2 (en) 2019-04-16
US11071770B2 (en) 2021-07-27
US8628929B2 (en) 2014-01-14
WO2008140814A1 (en) 2008-11-20
JP2010527000A (ja) 2010-08-05
JP2017026622A (ja) 2017-02-02
CA2965208C (en) 2022-06-14
EP2153228A4 (en) 2010-08-04
MX2009012174A (es) 2010-03-30
JP5749490B2 (ja) 2015-07-15

Similar Documents

Publication Publication Date Title
US11071770B2 (en) Methods for detecting cardiac damage
Pilebro et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)
AU2003259803B2 (en) Diagnosis and treatment of tuberous sclerosis
US20160061846A1 (en) Method for Evaluating Atherosclerotic Lesion, and Kit
Jong et al. Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging
US7695903B2 (en) Low-density lipoprotein receptor related protein-1 (LRP-1)in clearance of alzheimer's amyloid-beta peptide from the central nervous system
Ishibashi et al. Localization of parathyroid glands using technetium-99m-tetrofosmin imaging
AU2014202390B2 (en) Methods for detecting cardiac damage
Dali et al. Study of Short-term toxicity of Cyclophosphamide and Doxorubicin on the Cardiovascular System in women with Breast cancer treated at the center of radiation and chemotherapy at Tishreen University Hospital
Rogers et al. Simultaneous evaluation of pancreatic exocrine function and intestinal absorptive function in dogs with chronic diarrhea
Ede et al. Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results
KR102787762B1 (ko) 독성 간염의 진단 또는 예후 예측 마커 및 이를 이용한 독성 간염 진단 또는 예후 예측 방법
Jong¹ et al. pathobiology to identification of molecular targets for nuclear
KR20170135671A (ko) 간암의 진단 및 예후 예측용 바이오 마커 및 그의 용도
US20080207671A1 (en) Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
Paolo Spallarossa et al. Identification and Management of Immune Checkpoint Inhibitor–Related Myocarditis: Use Troponin Wisely

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130404

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241114